NEJMJClub
Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a).
New England Journal of Medicine · · Journal Article
Cho, Nicholls + more
Abstract ↗AI summary
The abstract is read at the publisher; the summary is JClub's.
Pelacarsen (80 mg monthly) did not reduce major adverse cardiovascular events versus placebo in 8322 patients with preexisting cardiovascular disease and lipoprotein(a) ≥70 mg/dL.
- Why it matters: Although pelacarsen lowers serum lipoprotein(a), its impact on cardiovascular outcomes in high-risk patients is uncertain.
- What they did: In an international randomized, placebo-controlled trial, patients received subcutaneous pelacarsen or matching placebo; the primary endpoint was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or urgent coronary revascularization.
- The result: Over a median 4.7 years, primary events occurred in 12.3% with pelacarsen and 12.1% with placebo (hazard ratio 1.02, 95% CI 0.90–1.15, P=0.76), including in those with baseline lipoprotein(a) ≥90 mg/dL (hazard ratio 1.00, 95% CI 0.87–1.15, P=0.99).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.